Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2002-05-30
2004-10-12
Kemmerer, Elizabeth (Department: 1647)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C536S023500, C536S023100, C435S325000, C435S252100, C435S254200, C370S300000
Reexamination Certificate
active
06803213
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel parathyroid hormone peptide (PTH) derivatives. In particular, the invention relates to PTH derivatives having one or more amino acid substitutions that confer PTH-1 receptor agonist or antagonist properties to the derivatives.
2. Description of Related Art
Full understanding of the complex biological roles of parathyroid hormone (PTH) and efforts to utilize its therapeutic potential require dissection of the multiple signaling patterns and cellular pathways of action of the hormone. PTH binds and activates specific receptors in renal and osseous target cells that also recognize PTH-related peptide (PTHrP) (Kronenberg, H., et al., “The PTH/PTHrP receptor: one receptor for two ligands,” in
Genetics of Endocrine and Metabolic Disorders
, Thakker, R., ed., Chapman & Hall, London (1997), pp. 389-420). In renal and osteoblastic cell lines, PTH triggers several parallel intracellular signaling responses, including activation of adenylyl cyclase (AC), protein kinase A (PKA), phospholipase C (PLC) and protein kinase C (PKC) and generation of second messengers such as cyclic AMP (cAMP), inositol trisphosphate (IP
3
), diacylglycerol and increased cytosolic free calcium (Ca
i
++
) (Abou-Samra, A. B., et al.,
Proc. Natl. Acad. Sci. USA
. 89(7):2732-2736 (1992); Azarani, A., et al.,
J. Biol. Chem
. 271(25):14931-14936 (1996); Bringhurst, F. R, et al.,
Endocrinology
132(5):2090-2098 (1993); Civitelli, R., et al.,
Am. J. Physiol
. 255(5 Pt 1):E660-667 (1988); Donahue, H. J., et al.,
J. Biol. Chem
. 263:13522-13527 (1988); Dunlay, R., and Hruska, K.,
Am. J. Physiol
. 258(2 Pt 2):F223-231 (1990); Fujimori, A., et al.,
Endocrinology
128(6):3032-3039 (1991); Fujimori, A., et al.,
Endocrinology
130(1):29-36 (1992); Guo, J., et al.,
Endocrinology
136(9):3884-3891 (1995); Janulis, M., et al.,
Endocrinology
133:713-719 (1993); Jouishomme, H., et al.,
J. Bone Miner. Res
. 9(6):943-949 (1994); Juppner, H., et al.,
Science
254(5034):1024-1026 (1991); Pines, M., et al.,
Bone
18(4):381-389 (1996); Seuwen, K., et al.,
Brit. J. Pharm
. 114(8):1613-1620 (1995); Siegfried, G., et al.,
Endocrinology
136(3):1267-1275 (1995).
To date, two structurally related but distinct species of PTH receptors have been cloned (Abou-Samra, A. B., et al.,
Proc. Natl. Acad. Sci. U.S.A
. 89(7):2732-2736 (1992); Usdin, T. B., et al.,
J. Biol. Chem
. 270(26):15455-15458 (1995); Schipani, E., et al.,
Endocrinology
132(5):2157-2165 (1993)). The first of these, type A, was isolated from both bone and kidney cells and shown to transduce multiple signaling responses to PTH-(1-34) or PTHrP(1-36) when heterologously expressed in cells that lack endogenous type 1 PTH/PTHrP receptors (hereinafter PTH-1 receptors) (Abou-Samra, A. B., et al.,
Proc. Natl. Acad. Sci. U.S.A
. 89(7):2732-2736 (1992); Azarani, A., et al.,
J. Biol. Chem
. 271(25):14931-14936 (1996); Bringhurst, F. R., et al.,
Endocrinology
132(5):2090-2098 (1993); Guo, J., et al.,
Endocrinology
136(9):3884-3891 (1995); Pines, M., et al.,
Bone
18(4):381-389 (1996); Jobert, A.-S., et al.,
Endocrinology
138(12):5282-5292 (1997); Schneider, H., et al.,
Eur. J. Pharm
. 246(2):149-155 (1993)).
Previous efforts to define the contributions of specific regions of the PTH molecule to its binding and signaling properties have been undertaken mainly by use of complex in vivo bioassays, organ cultures, isolated cell membranes or cell lines, generally of rodent origin, that may express more than one type of endogenous PTH-1 receptors (Janulis, M., et al.,
Endocrinology
133:713-719 (1993); Siegfried, G., et al.,
Endocrinology
136(3):1267-1275 (1995); Yamamoto, S., et al.,
Endocrinology
138:2066-2072 (1997); Jouishomme, H., et al.,
Endocrinology
130(1):53-60 (1992); Segre, G. V., et al.,
J. Biol. Chem
. 254:6980-6986 (1979); Tregear, G. W., and Potts, J. T., Jr.
Endocr. Res. Commum
. 2:561-567 (1975); Takasu, H., et al.,
Endocrinology
137(12):5537-5543 (1996); Orloff, J. J., et al.,
Am. J. Physiol
. 262(5 Pt 1):E599-607 (1992)).
Early structure/function studies of bovine PTH-(1-34), performed with isolated renal membranes, identified the key role of the carboxyl(C)-terminal bPTH-(25-34) region for receptor binding and of the amino(N)-terminus (i.e., Ser
1
) for AC activation (Segre, G. V., et al.,
J. Biol. Chem
. 254:6980-6986 (1979); Tregear, G. W., and Potts, J. T., Jr.
Endocr. Res. Commun
. 2:561-567 (1975)). Later work conducted in vitro with intact renal tubules or with cultured renal or bone cells, however, indicated that N-truncated analogs such as PTH-(3-34), although unable to stimulate AC, could fully activate PKC and could regulate certain PKC-dependent distal biologic responses (Janulis, M., et al.,
Endocrinology
133:713-719 (1993); Siegfried, G., et al.,
Endocrinology
136(3):1267-1275 (1995); Jouishomme, H., et al.,
Endocrinology
130(1):53-60 (1992)). Amino-truncated analogs of PTH-(1-34) also were found to increase PLC activity or Ca
j
++
in some cells (Donahue, H. J., et al.,
J. Biol. Chem
. 263:13522-13527 (1988); Fujimori, A., et al.,
Endocrinology
128(6):3032-3039 (1991); Siegfried, G., et al.,
Endocrinology
136(3):1267-1275 (1995)) though not in others (Reid, I. R, et al.,
Am. J. Physiol
. 253(1 Pt 1):E45-51 (1987); Tamura, T., et al.,
Biochem. Biophys., Res. Commun
. 159:1352-1358 (1989)). Studies of the signaling properties of the cloned PTH-1 receptor have focused almost exclusively upon activation of AC, PLC or C
i
++
(Abou-Samra, A. B., et al.,
Proc. Natl. Acad. Sci. U.S.A
. 89(7):2732-2736 (1992); Bringhurst, F. R, et al.,
Endocrinology
132(5):2090-2098 (1993); Guo, J., et al.,
Endocrinology
136(9):3884-3891 (1995); Pines, M., et al.,
Bone
18(4):381-389 (1996); Jobert, A.-S., et al.,
Endocrinology
138(12):5282-5292 (1997); Schneider, H., et al.,
Eur. J. Pharm
. 246(2):149-155 (1993)), although stimulation of PKC and of PKC-dependent ion transport by hPTH(1-34), hPTH-(3-34) and other hPTH fragments was reported in CHO cells transfected with rat PTH-1 receptor cDNA (Azarani, A., et al.,
J. Biol. Chem
. 271(25):14931-14936 (1996)).
Collectively, these observations have engendered the concept that the structural determinants for activation of AC/PKA signaling are distinct from those required for activation of PLC or PKC and that these reside, respectively, within the N- and C-terminal domains of PTH-(1-34) (Jouishomme, H., et al.,
J. Bone Miner. Res
. 9(6):943-949 (1994); Tregear, G. W., and Potts, J. T., Jr.
Endocr. Res. Commun
. 2:561-567 (1975); Whitfield, J. F., and Morley, P.
Trends Pharm. Sci
. 16(11):382-386 (1995)). In particular, the region hPTH-(29-32) was identified specifically as a critical PKC activation domain (Jouishomme, H., et al.,
J. Bone Miner. Res
. 9(6):943-949 (1994); Whitfield, J. F., and Morley, P.
Trends Pharm. Sci
. 16(11):382-386(1995)).
Compared with what is known from these studies of the rat PTH-1 receptor, much less information is available regarding the structural features of human PTH required for binding to the human PTH-1 receptor or for activation of its various signaling modes. Alanine-scanning mutagenesis has highlighted the importance of the C-terminal portion of hPTH-(1-34) for binding to the rat PTH-1 receptor (30). Functional studies of transfected human PTH receptors in COS-7 or HEK 293 cells have confirmed that hPTH-(1-34) activates AC and Ca
i
++
, although stimulation of PLC was not observed consistently and responses that were reported were modest (Pines, M., et al.,
Bone
18(4):381-389 (1996); Seuwen, K., et al.,
Brit. J. Pharm
. 114(8):1613-1620 (1995); Jobert, A.-S., et al.,
Endocrinology
138(12):5282-5292 (1997); Schneider, H., et al.,
FEBS Lett
. 351(2):281-285 (1994);). The effects of hPTH-(3-34) on Ca
i
++
are similarly controversial (Pines, M., et al.,
Bone
18(4):381-389 (1996); Jobert, A.-S., et al.,
Endocrinology
138(12):5282-5292 (1997)), while the roles of other regions of the hPTH
Bringhurst F. Richard
Gardella Thomas J.
Potts, Jr. John T.
Takasu Hisashi
Kemmerer Elizabeth
Sterne Kessler Goldstein & Fox P.L.L.C.
The General Hospital Corporation
Wegert Sandra
LandOfFree
Nucleic acids encoding modified parathyroid hormone does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nucleic acids encoding modified parathyroid hormone, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids encoding modified parathyroid hormone will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3265474